This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           April 02, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

SGR, ICD-10 delay ready to be signed into law
MedPage Today
The Senate voted to delay scheduled cuts in physician payments under Medicare and move the switch to ICD-10 billing codes to October 2015. The chamber passed a bill that delays by 12 months pending reimbursement cuts under Medicare's sustainable growth rate (SGR) payment formula. Physicians were to face 24 percent cuts in Medicare payments starting Tuesday unless Congress acted.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




MORE SGO ANNUAL MEETING COVERAGE


SGO wrap-up: Obesity, new drug, no-admit surgery
MedPage Today
MedPage Today wraps up its coverage of the 2014 SGO Annual Meeting.Highlights include:
  • Surgery or chemo for obese ovarian cancer patients?
  • Cost of obesity in endometrial cancer
  • PARP inhibitor active in BRCA ovarian cancer
  • Same-day discharge after hysterectomy

  • Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    GENETICS


    SGO recommends genetic testing for endometrial and ovarian cancer patients
    Cancer Network
    The Society of Gynecologic Oncology (SGO) recently issued two new clinical practice statements recommending genetic testing for all women with endometrial and ovarian cancers, regardless of family history. All women with ovarian, fallopian tube, or peritoneal cancer should receive genetic counseling and consider genetic testing regardless of age or family history, according to an SGO statement issued earlier this month.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    Advertisement
    PRODUCT SHOWCASE
      ChemoFx Improves Ovarian Cancer Outcomes
    ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
     


    INDUSTRY NEWS


    Glaxo withdraws application for ovarian cancer treatment
    The Wall Street Journal (Subscription required)
    Drug company GlaxoSmithKline PLC said it has withdrawn an application to the European Medicines Agency related to its ovarian-cancer treatment Votrient after analyzing data from a Phase III study. The application was for a variation to marketing authorization for Votrient in the European Union, Glaxo said. "We believe that, in spite of the improvement in progression free survival observed in our Phase III study, the totality of the evidence including these more mature [overall survival] data, do not support an overall positive benefit-risk for Votrient in this indication," said Rafael Amado, head of oncology research and development at Glaxo.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    FDA clears new version of Intuitive's da Vinci surgical robot
    Reuters
    Intuitive Surgical Inc said the U.S. Food and Drug Administration approved for marketing an upgraded version of its flagship robotic surgical system, sending the company's shares up as much as 15 percent. The company said it launched the device, da Vinci Xi Surgical System, in the United States on Tuesday. The device enables surgeons to perform complex procedures using a minimally invasive approach.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE




    OVARIAN CANCER


    Viewpoint: Is there a link between endometriosis and ovarian cancer?
    Medscape (Free login required)
    Researchers publishing in Human Reproduction found an increased risk for ovarian cancer among infertile women with endometriosis. One could consider elective oocyte or embryo cryopreservation to allow them to maintain fertility, should radical surgery be needed to manage their symptoms.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    Glycan-based biomarkers show promise for ovarian cancer detection
    HemOncToday
    Glycan-based biomarkers accurately detected epithelial ovarian cancer, suggesting they may have utility as a new diagnostic test, according to study results. Investigators used mass spectroscopy to evaluate the samples for different quantities of glycan expression. They then used a two-phase procedure for biomarker detection and confirmation. The researchers developed candidate classifiers of glycans that distinguished cases from controls, using a training set in the discovery phase. They later evaluated the classification ability of these candidate classifiers using independent test samples not used in the discovery phase.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    BREAST CANCER


    Decreased breast cancer recurrence and mortality following post-mastectomy radiotherapy
    2 minute medicine
    A study published online in The Lancet on March 19 found that 1) radiotherapy administered after mastectomy and axillary dissection decreased 10-year recurrence and 20-year mortality in women with node-positive breast cancer, and 2) no reduction in recurrence and mortality was shown for women with node-negative breast cancer who were given radiotherapy following mastectomy and axillary dissection.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


    BRCA1 cancer study suggests alternative to major surgery
    BioNews
    BRCA1 mutations put carriers at high risk of cancer by failing to protect cells against the effects of high levels of estrogen hormone found in breast and ovary tissue, researchers have established. A link between estrogen and BRCA1 had long been suspected, but the study confirms it and demonstrates the underlying mechanism. The information could allow the development of preventative treatment strategies using already available drugs as an alternative to the major surgery many women choose to have to reduce their cancer risk.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
    READ MORE


     



    Women's Cancer News
    Colby Horton, Vice President of Publishing, 469.420.2601
    Download media kit

    Jessica Taylor, Senior Medical Editor, 202-684-7169  
    Contribute news


    Inclusion of advertisements does not constitute SGO endorsement of company products or services.

    Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

    This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

    Recent issues

    March 26, 2014
    March 19, 2014
    March 12, 2014
    March 5, 2014






    7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063